Provided by Tiger Trade Technology Pte. Ltd.

IMMUNEONCO-B

3.475
+0.1253.73%
Volume:152.20K
Turnover:519.44K
Market Cap:1.49B
PE:-5.61
High:3.485
Open:3.475
Low:3.240
Close:3.350
52wk High:16.800
52wk Low:2.800
Shares:429.00M
HK Float Shares:418.00M
Volume Ratio:0.49
T/O Rate:0.04%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.619
ROE:-40.11%
ROA:-14.74%
PB:2.04
PE(LYR):-5.61
PS:8.65

Loading ...

ImmuneOnco-B Spends HK$236,900 to Buy Back 70,600 Shares on September 29

Stock News
·
Sep 29

IMMUNEONCO-B Repurchases 70,600 H Shares for HK$0.24 Million, Treasury Stock Rises to 2.34 Million Shares

Bulletin Express
·
Sep 29

ImmuneOnco Biopharma Unit Concludes 50 Million Yuan Capital Increase; Shares Climb 6%

MT Newswires Live
·
Sep 29

IMMUNEONCO-B (01541) Subsidiary Yiming Kaier Biopharmaceutical Technology (Shanghai) Completes Capital Increase

Stock News
·
Sep 28

ImmuneOnco H1 2026: Wider RMB165.50 Million Net Loss as Collaboration Fees Fall; Core Drug Advances to Phase III

Bulletin Express
·
Sep 28

IMMUNEONCO-B (01541) Unveils Groundbreaking Phase Ib/IIa Data for Next-Generation MCE Molecule, Reinforcing the Distinctive Edge of IMM0306

Stock News
·
Sep 24

ImmuneOnco Buys Back 92,400 H-Shares for HKD 0.30 Million, Lifting Treasury Stock to 2.27 Million

Bulletin Express
·
Sep 16

IMMUNEONCO-B Announces Share Buyback on September 16, Spending HK$297,600

Stock News
·
Sep 16

IMMUNEONCO-B (01541) Completes Share Buyback of 55,200 Shares on September 11

Stock News
·
Sep 11

Immuneonco Biopharma Files HKEX Next-Day Disclosure Return on Share Buyback, Cancellation

Reuters
·
Sep 11

ImmuneOnco Files HKEX Next-Day Disclosure Return on Share Repurchase for Treasury Shares

Reuters
·
Sep 10

ImmuneOnco Reports HKD 0.16 Million Share Buy-back; Treasury Shares Rise to 2.07 Million

Bulletin Express
·
Sep 04

ImmuneOnco Biopharma Files HKEX Next-Day Disclosure Return on Share Repurchase

Reuters
·
Sep 04

ImmuneOnco Nominates Dr. Liou Hsiou-Chi as Independent Non-Executive Director

Reuters
·
Aug 28

IMMUNEONCO-B Advances Phase II Trial for First-Line Advanced Liver Cancer Therapy With Initial Patient Dosing Completed

Stock News
·
Aug 27

ImmuneOnco Initiates Phase II Trial: First Patient Dosed with IMM2510 + IMM27M for Front-Line Advanced HCC Therapy

Bulletin Express
·
Aug 27

ImmuneOnco Doses First Patient in Phase II Trial of Imm2510-Imm27m Combo for First-Line Advanced Liver Cancer

Reuters
·
Aug 27

IMMUNEONCO-B Surges Over 10% in Afternoon Trade on Strong First-Half Revenue

Deep News
·
Aug 27

Hong Kong Stock Alert | IMMUNEONCO-B (01541) Surges Nearly 12% as Robust Cash Reserves and Major Clinical Milestones Drive Sentiment

Stock News
·
Aug 27

IMMUNEONCO-B Reports Interim Results with RMB 25.4 Million Revenue and Key Clinical Trial Milestones

Stock News
·
Aug 26